These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 26690657)

  • 21. Molecular mechanisms of resistance to kinase inhibitors and redifferentiation in thyroid cancers.
    Hofmann MC; Kunnimalaiyaan M; Wang JR; Busaidy NL; Sherman SI; Lai SY; Zafereo M; Cabanillas ME
    Endocr Relat Cancer; 2022 Nov; 29(11):R173-R190. PubMed ID: 35975971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted therapy in refractory thyroid cancer: current achievements and limitations.
    Brilli L; Pacini F
    Future Oncol; 2011 May; 7(5):657-68. PubMed ID: 21568681
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radioiodine therapy for thyroid cancer in the era of risk stratification and alternative targeted therapies.
    Pryma DA; Mandel SJ
    J Nucl Med; 2014 Sep; 55(9):1485-91. PubMed ID: 25134528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Drug approval: Cabozantinib monotherapy in advanced thyroid cancers refractory or not eligible for radioactive iodine treatment, after progression under previous systemic therapies].
    Matte P; Hadoux J
    Bull Cancer; 2022 Nov; 109(11):1103-1104. PubMed ID: 36220695
    [No Abstract]   [Full Text] [Related]  

  • 25. New Insights in Thyroid Cancer and p53 Family Proteins.
    Manzella L; Stella S; Pennisi MS; Tirrò E; Massimino M; Romano C; Puma A; Tavarelli M; Vigneri P
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28635633
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid carcinoma: a single-centre study of 54 patients.
    Jarzab B; Handkiewicz-Junak D; Roskosz J; Puch Z; Wygoda Z; Kukulska A; Jurecka-Lubieniecka B; Hasse-Lazar K; Turska M; Zajusz A
    Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1077-86. PubMed ID: 12783219
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial.
    Schneider TC; Abdulrahman RM; Corssmit EP; Morreau H; Smit JW; Kapiteijn E
    Eur J Endocrinol; 2012 Nov; 167(5):643-50. PubMed ID: 22918300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Theranostic Options for Radioiodine-Refractory Differentiated Thyroid Carcinoma: Recent Advances, Challenges, and Road Ahead.
    Satapathy S; Bal C
    Front Endocrinol (Lausanne); 2022; 13():924841. PubMed ID: 35903277
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activation of the IGF Axis in Thyroid Cancer: Implications for Tumorigenesis and Treatment.
    Manzella L; Massimino M; Stella S; Tirrò E; Pennisi MS; Martorana F; Motta G; Vitale SR; Puma A; Romano C; Di Gregorio S; Russo M; Malandrino P; Vigneri P
    Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31269742
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Systemic treatment of metastasized thyroid cancer-approved treatments and new approaches].
    Brandenburg T; Führer D
    Chirurg; 2020 Dec; 91(12):1038-1043. PubMed ID: 33025108
    [TBL] [Abstract][Full Text] [Related]  

  • 31. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
    Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
    Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Advanced radioiodine-refractory differentiated thyroid cancer].
    Spitzweg C; Auernhammer CJ; Geisler J; Böck S; Heinemann V; Bartenstein P; Göke B
    Dtsch Med Wochenschr; 2015 Feb; 140(3):168-71. PubMed ID: 25658401
    [No Abstract]   [Full Text] [Related]  

  • 33. Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy.
    Schechter RB; Nagilla M; Joseph L; Reddy P; Khattri A; Watson S; Locati LD; Licitra L; Greco A; Pelosi G; Carcangiu ML; Lingen MW; Seiwert TY; Cohen EE
    Cancer Lett; 2015 Apr; 359(2):269-74. PubMed ID: 25641339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical review 158: Beyond radioiodine: a review of potential new therapeutic approaches for thyroid cancer.
    Braga-Basaria M; Ringel MD
    J Clin Endocrinol Metab; 2003 May; 88(5):1947-60. PubMed ID: 12727938
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Recombinant human TSH stimulation in radioiodine treatment of disseminated differentiated thyroid cancer--update of current and our own experiences].
    Hasse-Lazar K; Handkiewicz-Junak D; Roskosz J; Szpak-Ulczok S; Krajewska J; Jurecka-Lubieniecka B; Jarzab B
    Endokrynol Pol; 2006; 57(4):445-50. PubMed ID: 17006851
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcomes and Prognostic Factors in Radioiodine Refractory Differentiated Thyroid Carcinomas.
    Wassermann J; Bernier MO; Spano JP; Lepoutre-Lussey C; Buffet C; Simon JM; Ménégaux F; Tissier F; Leban M; Leenhardt L
    Oncologist; 2016 Jan; 21(1):50-8. PubMed ID: 26675742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical trials for progressive differentiated thyroid cancer: patient selection, study design, and recent advances.
    Schlumberger M; Sherman SI
    Thyroid; 2009 Dec; 19(12):1393-400. PubMed ID: 20001721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An update on molecular biology of thyroid cancers.
    Omur O; Baran Y
    Crit Rev Oncol Hematol; 2014 Jun; 90(3):233-52. PubMed ID: 24405857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strategies of radioiodine ablation in patients with low-risk thyroid cancer.
    Schlumberger M; Catargi B; Borget I; Deandreis D; Zerdoud S; Bridji B; Bardet S; Leenhardt L; Bastie D; Schvartz C; Vera P; Morel O; Benisvy D; Bournaud C; Bonichon F; Dejax C; Toubert ME; Leboulleux S; Ricard M; Benhamou E;
    N Engl J Med; 2012 May; 366(18):1663-73. PubMed ID: 22551127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thyroid suppression and radioiodine treatment for differentiated thyroid cancer.
    Rösler H
    Arch Otolaryngol Head Neck Surg; 1987 Jul; 113(7):778-9. PubMed ID: 3580165
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.